Sanofi and NIH researchers develop "three-in-one" antibodies as a potential breakthrough intervention for HIV/AIDS

CAMBRIDGE, Mass., Sept. 20, 2017 /PRNewswire/ -- In a landmark study published in the journal Science today, researchers produced genetically engineered antibodies with the highest activity and breadth of coverage yet seen against human immunodeficiency virus (HIV-1). Natural...